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Prevention of hospitalisation in bipolar disorder 
Abstract 
It is well recognised that medications have an important role to play in preventing 
relapse in bipolar disorder. The impact these treatments have on rates of admission 
to hospital in particular has been less well studied. We combined data on 
hospitalisation from 11 randomised controlled trials in a network meta-analysis. We 
find that the published evidence demonstrates significant reductions in admission 
rates compared to placebo from lithium (RR 0.44, 95% CI 0.32 to 0.59), valproate 
(RR 0.50, 95% CI 0.28 to 0.90), the combination of lithium and valproate (RR 0.50, 
95% CI 0.28 to 0.90), carbamazepine (RR 0.46, 95% CI 0.29 to 0.73), and 
olanzapine (RR 0.27, 95% CI 0.16 to 0.43). The evidence base contributing to these 
estimates remains fairly small, leading to broad confidence intervals for estimates of 
effect. More precise estimates could be obtained if unpublished outcomes data from 
other trials in this area became available. Several pharmacological treatments 
appear to be effective at reducing the need for hospital admission in people with 
bipolar disorder. 
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Letter 
It is well established that pharmacological treatments for bipolar disorder can prevent 
relapse (Goodwin et al., 2016). Strong evidence for this comes from over thirty 
randomised controlled trials. These data have been combined using conventional 
pair-wise meta-analysis (Beynon et al., 2009), and more recently through network 
meta-analysis (Miura et al., 2014), synthesising evidence from both direct and 
indirect treatment comparisons to generate best available estimates of effect. 
While most treatment of bipolar disorder takes place in the community, for some 
people episodes of illness can lead to the need for admission to hospital. These 
admissions both act as a marker of serious relapse, associated with risks needing 
inpatient care, indicate inevitable social disruption, and also substantial economic 
impact. It has been estimated that the majority of healthcare costs attributed to 
bipolar disorder are due to hospitalisation (Young et al., 2011). The previous network 
meta-analysis (Miura et al., 2014) did not address the magnitude of effect on hospital 
admission rates of pharmacological treatment, although this is a clinically meaningful 
and pragmatic outcome measure for maintenance treatment. We sought to address 
this question from the available literature. 
We identified 11 randomised controlled trials of pharmacological agents for the 
prevention of relapse in bipolar disorder that had published data on hospital 
admission rates by treatment allocation (Coxhead et al., 1992; Dunner et al., 1976; 
Esparon et al., 1986; Fieve et al., 1976; Geddes et al., 2010; Kleindienst and Greil, 
2000; Lusznat et al., 1988; Prien, Caffey, et al., 1973; Prien, Klett, et al., 1973; 
Tohen et al., 2006, 2005). These studies compared eight treatment strategies. They 
are a subset of the 33 trials previously identified reporting effects on symptomatic 
relapse (Miura et al., 2014). We combined these outcome data in a random effects 
network meta-analysis using R (version 3.2.4) with packages meta (version 4.4) and 
netmeta (version 0.9) (Rücker, 2012). Code available from the authors on request. 
Figure 1 near here 
We find that the published literature indicates significant reductions in admission 
rates compared to placebo from lithium (RR 0.44, 95% CI 0.32 to 0.59), valproate 
(RR 0.50, 95% CI 0.28 to 0.90), the combination of lithium and valproate (RR 0.50, 
95% CI 0.28 to 0.90), carbamazepine (RR 0.46, 95% CI 0.29 to 0.73), and 
olanzapine (RR 0.27, 95% CI 0.16 to 0.43). Estimates were consistent with either 
harm or benefit for both imipramine (RR 1.13, 95% CI .51 to 2.50), and the 
combination of flupenthixol with lithium (RR 1.50, 95% CI 0.08 to 26.85). 
The evidence base contributing to these estimates remains fairly small, leading to 
broad confidence intervals for estimates of effect, and new data could substantially 
affect these estimates. No hospitalisation data were available for other widely used 
treatments, such as quetiapine, which have been shown elsewhere to reduce 
relapse rates. Although it is unrealistic to expect many new trials of such treatments 
to be reported in the short term, improved estimates could be obtained if unpublished 
outcomes data from existing trials in this area were made available. 
The estimates of effect may have been differentially affected by use of enrichment 
designs in some studies (Cipriani et al., 2013), and thresholds for hospital admission 
may well vary between settings depending on bed availability or provision of 
alternative crisis services. It will be important to consider these findings in the context 
of observational data (Joas et al., 2015); contrasts between experimental and 
observational data have been recently described for efficacy in prevention of relapse 
in bipolar disorder assessed by rates of monotherapy treatment failure (Hayes et al., 
2016). 
The reductions in rates of hospital admission from this analysis are fairly similar 
between most agents where data are available. This contrasts with relapse 
prevention efficacy for episodes of mania and depression where substantial 
differences in relative effects are seen, correlating with differences in efficacy in the 
treatment of acute episodes (Miura et al., 2014; Taylor, 2014). It is possible that the 
broad confidence intervals surrounding estimates for each agent may obscure 
underlying differences in effect that could emerge should further data become 
available. 
Pharmacological treatments are not the sole approach likely to affect hospital 
admission rates. Group psychoeducation, for example, has a developing evidence 
base in relapse prevention for bipolar disorder (Bond and Anderson, 2015), and a 
specialist mood disorder clinic model combining medication management, following 
BAP prescribing guidelines (Goodwin et al., 2016), with a group programme 
achieved a substantial reduction in hospitalisation (Kessing et al., 2013). However, 
taken together, the published data from randomised controlled trials indicate that 
pharmacological agents can be an effective means of reducing need for hospital 
admission in people with bipolar disorder. 
Legends 
Figure 1. Best estimates for Relative Risk (RR) versus placebo for rates of hospital 
admission for pharmacological treatments for bipolar disorder. Random effects 
model; 95% Confidence Intervals (CI) shown. 
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